within Pharmacolibrary.Drugs.ATC.N;

model N06BA01_1
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 4.5e-05,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0027,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0078,
    k12             = 7.3,
    k21             = 7.3
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N06BA01_1</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Amfetamine (amphetamine) is a central nervous system stimulant used in the treatment of attention deficit hyperactivity disorder (ADHD), narcolepsy, and, historically, obesity. It acts primarily by increasing synaptic concentrations of dopamine and norepinephrine. Amfetamine is approved for medical use in several countries, but has limited indications due to dependence and abuse potential.</p><h4>Pharmacokinetics</h4><p>Healthy adults, intravenous administration, single bolus dose.</p><h4>References</h4><ol><li><p>White, S, et al., &amp; Owens, SM (2011). Gestation time-dependent pharmacokinetics of intravenous (+)-methamphetamine in rats. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 39(9) 1718–1726. DOI:<a href=\"https://doi.org/10.1124/dmd.111.039446\">10.1124/dmd.111.039446</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21632964/\">https://pubmed.ncbi.nlm.nih.gov/21632964</a></p></li><li><p>Martínez-Clemente, J, et al., &amp; Escubedo, E (2013). Mephedrone pharmacokinetics after intravenous and oral administration in rats: relation to pharmacodynamics. <i>Psychopharmacology</i> 229(2) 295–306. DOI:<a href=\"https://doi.org/10.1007/s00213-013-3108-7\">10.1007/s00213-013-3108-7</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23649883/\">https://pubmed.ncbi.nlm.nih.gov/23649883</a></p></li><li><p>Kelečević, I, et al., &amp; Mijatović Jovin, V (2024). Metaphedrone (3-Methylmethcathinone): Pharmacological, Clinical, and Toxicological Profile. <i>Medicina (Kaunas, Lithuania)</i> 60(3) –. DOI:<a href=\"https://doi.org/10.3390/medicina60030466\">10.3390/medicina60030466</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38541192/\">https://pubmed.ncbi.nlm.nih.gov/38541192</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N06BA01_1;
